Please enable JavaScript.
Coggle requires JavaScript to display documents.
Therapeutic Management of Skin Pathologies - Coggle Diagram
Therapeutic Management of Skin Pathologies
Psoriasis
Mild ---> Moderate Psoriasis
treatments
Vitamin D analogs
Steroids
Phototherapy: UV light supressess production of pro-inflammatory cytikines
phosphodiesterase inhibitors (PD4)
Th1 & Th17
excess keratinocyte proliferation
Moderate ---> Severe Psoriasis
steroids
immunosupressive agents
anti-proliferative drugs
Targeting T-cells
cyclosporine
Retinoids
altering TF profiles of keratinocytes (dec. proliferation)
pro-biologics
monoclonal antibodies
TNF-alpha target
adalimumab, etanercept
better, more specific therapeutics
ustekinumab
targets a common subunit ofIL-23 & IL-12
even better
risakizumab
developed to specifically target IL-23 alone
even, even better
secukinumab and bimekizumab have been developed targeting IL-17A, and IL-17A/IL-17F, respectively.
bimekizumab was shown to have increased efficacy with comparable side effects, indicating that targeting a broader spectrum of IL-17 isoforms may be more effective than targeting a single isoform.
Atopic Dermatitis (Eczema)
IgE; Type I hypersensitivity
Genetic risk factors are associated
ex: mutations in the gene encoding a protein known as filaggrin
clinical managment
mild ---> moderate
Maintaining skin hydration w/ emollients & mosturizers
Avoiding things that dry out or irritate the skin
Controlling pruritis
Corticosteroids
PD4 inhibitors
Phototherapy to reduce histamine production by mast cells and basophil
Systemic therapies with:
Oral antihistamines
Cyclosporine
moderate --> severe
same as mild to moderate plus these additional measures
Systemic therapies with
Cyclosporine
Methotrexate
Monoclonal antibodies
Dupilimab
Dupilimab is a monoclonal antibody that targets the action of IL-4 and IL-13, cytokines produced as part of the type 2 immune response by Th2 lymphocytes.
Dupilimab binds to the common subunit and so blocks signaling from both receptors.
Dupilimab is an antagonist for the IL-4 and IL-13 receptors, which share a common subunit.
abrocitinib
Pemphigus
P → d
:
p
emphigus has
d
esmosome problems
Desmosomes
Cell ↔ cell adhesion
Connects: keratinocyte to keratinocyte
autoimmune IgG antibodies against desmoglein 3
glucorticoids
rituxumab
suppresses IgG production by targeting CD20 expressed on the surface of many B lymphocyte progenitor cells
